Despite many people believing the HIV crisis is “solved,” HIV remains a critical public health issue with more than 31,000[1] new diagnoses in the US each year.
Thankfully, as science and research have advanced, there are many tools available to help prevent HIV, including PrEP (pre-exposure prophylaxis) which is medicine that prevents people from getting HIV. PrEP, when taken as indicated, is highly effective, and yet many who might benefit do not receive a prescription.

http://apretude.com/

According to preliminary data released by the CDC[2], in 2022, only about 36% of the 1.2 million people who could benefit from PrEP were prescribed it.

The CDC[3] also estimates that only 10% for women who could benefit from PrEP receive a prescription for it.

October 21 marks the start of PrEP Aware Week which shines a light on the importance of HIV prevention and the communities that are disproportionately impacted by HIV. The dedicated week is a time to educate everyone on the incidence rates of HIV, who could benefit from PrEP, and where to learn more about the different options available, including a daily pill or a long-acting injectable.
On Wednesday, October 23, Dr. Kimberly Smith, Head of Research and Development at ViiV Healthcare, will discuss ViiV’s comprehensive and innovative approach to HIV prevention and treatment and the role of prevention in ending the HIV epidemic once and for all.

Interview courtesy: ViiV Healthcare

The post THE ROLE OF PREVENTION IN ENDING THE HIV EPIDEMIC FOR ALL appeared first on Good News!.

HERE TO TALK ABOUT THESE IMPORTANT FINDINGS AND HOW THEY MAY HELP ADDRESS AN ONGOING AND UNMET NEED IN THE HIV COMMUNITY IS DR. HARMONY GARGES (GAR-JES), CHIEF MEDICAL OFFICER FROM ViiV (VEEV) HEALTHCARE.

BIO:

Dr. Harmony Garges is the Chief Medical Officer at ViiV Healthcare – the only pharmaceutical company 100% dedicated to HIV – where she is responsible for Regulatory, Safety and Medical Affairs across the company’s innovative pipeline and portfolio. Just like the company she works for, Harmony’s guiding mission is to ensure that no person living with HIV is left behind.

After obtaining her MD degree and completing her pediatrics residency at Duke University, Harmony pursued her interest in infectious diseases further with fellowships in Pediatric Infectious Diseases and Medical Microbiology at Duke, along with her MPH in Epidemiology from the University of North Carolina at Chapel Hill. Following her training, Harmony maintained an active clinical practice, providing care to children and adolescents living with HIV and other infectious diseases.

In 2005, Harmony joined GSK’s HIV program in the Infectious Diseases group, working on global development programs as a project physician leader. In this role she oversaw three successful New Drug and Marketing Authorization Applications and provided medical leadership and strategy for the development of various other anti-infectives including the first human trials of dolutegravir – the most prescribed HIV medicine in the world.

Subsequently, Harmony joined the Global Clinical Safety and Pharmacovigilance team at GSK, where she provided safety strategy and governance for several large global clinical development programs in the pharmaceutical space. She then led a large, global team overseeing the safety aspects of GSK’s large Classic and Established Medicines portfolio. From there, she joined the GSK Consumer Health business, where she spent three years as the Chief Medical Officer. She then joined ViiV Healthcare in 2016 and has held several roles in Global Medical Affairs before assuming her current role of Chief Medical Officer at the company in 2019.

#hiv #disease #aids #clinicaldata #dailypills #viiv #drharmonygarges #cabenuva #healthcare #medicalofficer #infectiousdiseases

The post IT MAY SURPRISE YOU TO LEARN THAT EACH YEAR, TENS OF THOUSANDS OF PEOPLE IN THIS COUNTRY ARE DIAGNOSED WITH HIV. WORLDWIDE, ROUGHLY 39-MILLION PEOPLE LIVE WITH THE DISEASE. RESEARCHERS AND SCIENTISTS STUDYING HIV RECENTLY ATTENDED A GLOBAL SUMMIT… appeared first on Good News!.

Incredible advancements have been made in HIV care since the beginning of the epidemic, and today, people living with HIV who have access to medication can expect to live as long as the general population.1 With nearly half of people living with HIV in the U.S. over the age of 50, HIV research and treatment efforts have shifted to consider how to optimize care over the long-term and reduce the number of medications in a complete regimen.2

New data at AIDS 2022 will focus on innovative treatment options that address these considerations and meet the evolving needs of the HIV community. Data include two-drug regimens that reduce the number of antiretroviral medicines people are exposed to every day and treatments for long-term survivors who have developed resistance to other HIV therapies.

Dr. Harmony Garges, Chief Medical Officer at ViiV Healthcare, discuss key data from the conference, HIV care as patients grow older and where treatment may be headed next.

Interview courtesy: ViiV Healthcare
https://www.dovato.com/
https://www.rukobia.com/

#hiv #hivcare #aids #scientists #advocates #drharmonygarges #communitymembers #research #viivhealthcare #health #medication #treatment #drugs #therapies #medical #patients #data #harmonygarges #viiv #healthcare

The post HIV CONFERENCE, THE LARGEST, UNDERSCORES CONTINUED INNOVATION IN HIV CARE appeared first on Good News!.